Here are the DEF 14A proxy statements from Immunocore Holdings plc (IMCR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow IMCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMCR filings page.
Immunocore Holdings plc has called its 2026 Annual General Meeting for May 27, 2026, at 2:00 p.m. London time, as a hybrid meeting in London and online via meetnow.global/IHCAGM2026. Ordinary shareholders can attend in person with a QR code or participate electronically.
Shareholders will vote on 10 ordinary resolutions, including the re-appointment of three Class II directors (Siddharth Kaul, William Pao and Kristine Peterson), an advisory say‑on‑pay vote for named executive officers, and approval of the U.K. directors’ remuneration report. Other items cover ratifying and re‑appointing Deloitte LLP as both U.S. independent auditor and U.K. statutory auditor, authorizing the audit committee to set the U.K. audit fee, and receiving and adopting the 2025 U.K. Annual Report.
The final proposal seeks authority for the company and its subsidiaries to make limited political donations and incur political expenditure, capped at £50,000 in each of three categories. The board unanimously recommends that shareholders vote FOR all resolutions. As of April 2, 2026, there were 50,831,928 ordinary shares outstanding and entitled to vote.